Viatris And Sandoz May Market Injectafer Generic In US From 2026
ANDA Disputes Regarding Ferric Carboxymaltose Are Now Settled
After over two years of litigation, Vifor and American Regent have reached agreements with Viatris’ Mylan and Sandoz regarding their generic ferric carboxymaltose products, allowing both companies to bring rivals to market ahead of the expiry of certain US patents.
You may also be interested in...
Facing down a key patent infringement trial beginning on 19 May, Viatris is continuing to eye an opportunity to launch its Breyna generic version of AstraZeneca’s Symbicort before patent expiry in 2023.
A bipartisan group of senators has written to the US Patent and Trademark Office, urging it to tackle the impact of patent thickets on the generic and biosimilar drug industries.
Utilizing the genetic overlap between frontotemporal dementia and amyotrophic lateral sclerosis, AviadoBio is seeking to develop gene therapies which can stop both these devastating diseases in their tracks using novel delivery techniques.